Contrary to the benign disease group, there was no significant change for LH in the endometrial carcinoma group immediately after the FDA warning was issued (pre FDA: April 2013–March 2014) vs. afterwards (post: May 2014–April 2015). Here, PLOD1 is linked to endometrial carcinoma.